Emergence of New Improved Vaccinations Display High Therapeutic Potential against Human Papillomavirus

Human papillomavirus (HPV) is any of over 150 related viruses and every HPV in the huge family is imparted a unique number, which is the HPV type. The name of HPV originated after the warts, i.e. papillomas, caused by certain HPV types. Other HPV types may cause a number of cancers, specifically cervical cancer. 

Over 40 types of HPVs may infect the human genital areas. Therefore, there are a number of vaccines utilized for the prevention of common HPV types, commonly known as HPV therapeutics. The drug classes applied against HPV infections include keratolytic agents, immunomodulators, sinecatechins, and anti-neoplastic agents. TMR, a market intelligence company, has released data about the immunomodulators therapeutic drug class and describes its major types along with presenting their primary way of functioning.

Browse Market Research Report of Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market: http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html

Immunomodulators: Immunomodulators are utilized in the treatment of externally occurring anogenital warts, also known as condylomata acuminate. In 2013, immunomodulators represented the biggest share in the global market for HPV therapeutics, due to their cost-effectiveness, enhanced efficiency, and noninvasive mode of treatment. Immunomodulators are further classified into:

• Imiquimod: Imiquimod is a derivative of imidazoquinolinamine and is accompanied by nil in-vitro anti-viral activity. Macrophages are induced by imiquimod to secrete cytokines, namely interferon alfa, interleukin (IL)-2, and gamma. Imiquimod is given as an individual dose and, via extensive studies, has emerged as a new therapy in place of other treatments against HPV. Imiquimod is found to be more effective in women as compared to men.

• Interferon alfa-n3: This is a protein product manufactured with the help of the process of single species recombinant DNA. It can additionally be obtained via donated human leukocytes’ pooled units induced via incomplete infection from a murine virus. This agent is utilized in intralesional treatment related to recurring or refractory condyloma acuminatum. It is especially useful in patients that have not responded well to other treatments such as surgical excision, podophyllin, and laser therapy.

Browse Market Research Press Release of Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market: http://www.transparencymarketresearch.com/pressrelease/hpv-cmv-therapeutics-market.htm

• Interferon alfa-2b: This is also a protein product manufactured via recombinant DNA technology. The immunomodulatory effects of interferon alfa-2b include improvement in the macrophages’ phagocytic activity, suppressing the spreading of tumor cells, and increasing the lymphocyte cytotoxicity. The treatment pattern of interferon alfa-2b is similar to that of interferon alfa-n3.

In addition, recently there are some new vaccines being developed for the treatment of HPV. For instance, Merck & Co., Inc. has made a vaccine named Gardasil, also known as recombinant human papillomavirus vaccine or Silgard. This is a type of vaccine utilized in preventing specific strains of HPV, especially HPV types 11, 6, 18, and 16. This vaccine was first approved in 2008 by the FDA for utilization in 41 states of the U.S. In December 2014, a new Gardasil-based vaccine, named Gardasil 9, has been approved by the FDA for protection against all the HPV strains that came under the ambit of the first generation of Gardasil vaccines and additionally 5 other kinds of HPV strains, namely HPV-33, HPV-31, HPV-58, HPV-45, and HPV-31.